Terms: = Lung cancer AND VHL, HRCA1, P40337, 7428, ENSG00000134086, RCA1, VHL1 AND Treatment
33 results:
1. Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors.
Fan H; Zhou Z; Yu D; Sun J; Wang L; Jia Y; Tian J; Mi W; Sun H
Bioorg Chem; 2023 Nov; 140():106793. PubMed ID: 37683536
[TBL] [Abstract] [Full Text] [Related]
2. LncRNA MALAT1 promotes growth and metastasis of head and neck squamous cell carcinoma by repressing vhl through a non-canonical function of EZH2.
Duan Y; Yue K; Ye B; Chen P; Zhang J; He Q; Wu Y; Lai Q; Li H; Wu Y; Jing C; Wang X
Cell Death Dis; 2023 Feb; 14(2):149. PubMed ID: 36813772
[TBL] [Abstract] [Full Text] [Related]
3. Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies.
Ruggeri RM; Benevento E; De Cicco F; Fazzalari B; Guadagno E; Hasballa I; Tarsitano MG; Isidori AM; Colao A; Faggiano A;
J Endocrinol Invest; 2023 Feb; 46(2):213-234. PubMed ID: 36038743
[TBL] [Abstract] [Full Text] [Related]
4. Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations.
Principe DR
Sci Rep; 2022 Jul; 12(1):11490. PubMed ID: 35798829
[TBL] [Abstract] [Full Text] [Related]
5. Downregulation of lncRNA APCDD1L-AS1 due to DNA hypermethylation and loss of vhl protein expression promotes the progression of clear cell renal cell carcinoma.
Yang W; Zhou J; Zhang Z; Zhang K; Xu Y; Li L; Cai L; Gong Y; Gong K
Int J Biol Sci; 2022; 18(6):2583-2596. PubMed ID: 35414787
[No Abstract] [Full Text] [Related]
6. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract] [Full Text] [Related]
7. JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis.
Ito T; Masui T; Komoto I; Doi R; Osamura RY; Sakurai A; Ikeda M; Takano K; Igarashi H; Shimatsu A; Nakamura K; Nakamoto Y; Hijioka S; Morita K; Ishikawa Y; Ohike N; Kasajima A; Kushima R; Kojima M; Sasano H; Hirano S; Mizuno N; Aoki T; Aoki T; Ohtsuka T; Okumura T; Kimura Y; Kudo A; Konishi T; Matsumoto I; Kobayashi N; Fujimori N; Honma Y; Morizane C; Uchino S; Horiuchi K; Yamasaki M; Matsubayashi J; Sato Y; Sekiguchi M; Abe S; Okusaka T; Kida M; Kimura W; Tanaka M; Majima Y; Jensen RT; Hirata K; Imamura M; Uemoto S
J Gastroenterol; 2021 Nov; 56(11):1033-1044. PubMed ID: 34586495
[TBL] [Abstract] [Full Text] [Related]
8. Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade.
Terry S; Dalban C; Rioux-Leclercq N; Adam J; Meylan M; Buart S; Bougoüin A; Lespagnol A; Dugay F; Moreno IC; Lacroix G; Lorens JB; Gausdal G; Fridman WH; Mami-Chouaib F; Chaput N; Beuselinck B; Chabaud S; Barros-Monteiro J; Vano Y; Escudier B; Sautès-Fridman C; Albiges L; Chouaib S
Clin Cancer Res; 2021 Dec; 27(24):6749-6760. PubMed ID: 34407968
[TBL] [Abstract] [Full Text] [Related]
9. Clinicopathological characteristics of primary peritoneal epithelioid mesothelioma of clear cell type: A case report.
Du XM; Wei YP; Gao Y; Li Z; Zhang JM; Chang H; Li Y
Medicine (Baltimore); 2021 Mar; 100(12):e25264. PubMed ID: 33761726
[TBL] [Abstract] [Full Text] [Related]
10. Discovery of potent small molecule PROTACs targeting mutant EGFR.
Zhao HY; Yang XY; Lei H; Xi XX; Lu SM; Zhang JJ; Xin M; Zhang SQ
Eur J Med Chem; 2020 Dec; 208():112781. PubMed ID: 32883633
[TBL] [Abstract] [Full Text] [Related]
11. Third-line sunitinib treatment in a
Li X; Gao L; Zhang L; Sun H; Gou H
Cancer Biol Ther; 2020 Sep; 21(9):785-789. PubMed ID: 32552305
[TBL] [Abstract] [Full Text] [Related]
12. Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.
Shukuya T; Oyanagi J; Serizawa M; Watanabe M; Yamamoto N; Koh Y
Anticancer Res; 2020 Apr; 40(4):1867-1874. PubMed ID: 32234874
[TBL] [Abstract] [Full Text] [Related]
13. Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance.
Sun N; Ren C; Kong Y; Zhong H; Chen J; Li Y; Zhang J; Zhou Y; Qiu X; Lin H; Song X; Yang X; Jiang B
Eur J Med Chem; 2020 May; 193():112190. PubMed ID: 32179332
[TBL] [Abstract] [Full Text] [Related]
14. A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease.
Yuan G; Liu Q; Tong D; Liu G; Yi Y; Zhang J; Zhang Y; Wang LA; Wang L; Chen R; Guan Y; Yi X; Lan W; Jiang J
Cancer Biol Ther; 2018; 19(9):766-772. PubMed ID: 29947576
[TBL] [Abstract] [Full Text] [Related]
15. What determines mortality in malignant pheochromocytoma? - Report of a case with eighteen-year survival and review of the literature.
Andrade MO; Cunha VSD; Oliveira DC; Moraes OL; Lofrano-Porto A
Arch Endocrinol Metab; 2018; 62(2):264-269. PubMed ID: 29768630
[TBL] [Abstract] [Full Text] [Related]
16. vhl deletion in osteoblasts boosts cellular glycolysis and improves global glucose metabolism.
Dirckx N; Tower RJ; Mercken EM; Vangoitsenhoven R; Moreau-Triby C; Breugelmans T; Nefyodova E; Cardoen R; Mathieu C; Van der Schueren B; Confavreux CB; Clemens TL; Maes C
J Clin Invest; 2018 Mar; 128(3):1087-1105. PubMed ID: 29431735
[TBL] [Abstract] [Full Text] [Related]
17. Classifying cancer genome aberrations by their mutually exclusive effects on transcription.
Dayton JB; Piccolo SR
BMC Med Genomics; 2017 Dec; 10(Suppl 4):66. PubMed ID: 29322935
[TBL] [Abstract] [Full Text] [Related]
18. Renal cell carcinoma.
Hsieh JJ; Purdue MP; Signoretti S; Swanton C; Albiges L; Schmidinger M; Heng DY; Larkin J; Ficarra V
Nat Rev Dis Primers; 2017 Mar; 3():17009. PubMed ID: 28276433
[TBL] [Abstract] [Full Text] [Related]
19. Benefit of Sunitinib in the treatment of pulmonary primitive neuroectodermal tumors: a case report and literature review.
Zhang C; Zhang J; Wang G; Xu J; Li Y; Guo Q; Zheng T; Zhang Y
Oncotarget; 2016 Dec; 7(52):87543-87551. PubMed ID: 27974690
[TBL] [Abstract] [Full Text] [Related]
20. K63-polyubiquitinated HAUSP deubiquitinates HIF-1α and dictates H3K56 acetylation promoting hypoxia-induced tumour progression.
Wu HT; Kuo YC; Hung JJ; Huang CH; Chen WY; Chou TY; Chen Y; Chen YJ; Chen YJ; Cheng WC; Teng SC; Wu KJ
Nat Commun; 2016 Dec; 7():13644. PubMed ID: 27934968
[TBL] [Abstract] [Full Text] [Related]
[Next]
